Related Experiment Video
Updated: Apr 28, 2026
05:44
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
Published on: October 13, 2023
2.6K
Allopregnanolone and neuroinflammation: a focus on multiple sclerosis
Farshid Noorbakhsh1, Glen B Baker2, Christopher Power3
1Department of Immunology, Faculty of Medicine, Tehran University of Medical Sciences Tehran, Iran.
Frontiers in Cellular Neuroscience
|June 12, 2014
Summary
Allopregnanolone (ALLO), a neurosteroid, shows promise in treating neurodegenerative diseases like multiple sclerosis (MS). ALLO may reduce neuroinflammation and improve neurological function by influencing both neural cells and immune cells.
Area of Science:
- Neuroscience
- Immunology
- Endocrinology
Background:
- Allopregnanolone (ALLO) is a neurosteroid that modulates GABA-A receptors, impacting neural cell functions like survival and migration.
- ALLO plays a role in neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis (MS).
- Altered ALLO biosynthesis is observed in MS patient brain tissue and animal models.
Purpose of the Study:
- To review the role of ALLO in the pathogenesis of MS.
- To discuss potential cellular and molecular pathways influenced by ALLO in MS.
- To explore ALLO's impact on neuroinflammation and neuroregeneration in MS.
Main Methods:
- Literature review of studies on allopregnanolone and multiple sclerosis.
- Analysis of research on neurosteroid biosynthesis and GABA-A receptor interactions.
- Examination of data from animal models of autoimmune demyelination and human MS studies.
Main Results:
- ALLO administration ameliorates neurobehavioral deficits, neuropathology, and CNS inflammation in animal models of MS.
- ALLO exhibits neuroprotective, growth-promoting, and differentiation-promoting effects on neurons and glial cells.
- Evidence suggests ALLO may modulate leukocyte biology and neuroinflammatory mechanisms independently of its neuroregenerative actions.
Conclusions:
- ALLO holds therapeutic potential for multiple sclerosis, impacting both neurodegenerative and neuroinflammatory processes.
- Further research into ALLO's mechanisms in MS pathogenesis is warranted.
- ALLO's dual role in neuroprotection and immune modulation suggests a complex therapeutic profile for MS.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
19
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
19
01:23Alzheimer Disease ll: Pathophysiology
32
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
32
01:37Neural Regulation
34.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.6K
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:29Alzheimer Disease l: Introduction
20
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
20
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K